German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks Therapeutics for around ...

SpringWorks Therapeutics SWTX announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human ...

German healthcare and materials group Merck KGaA (OTCPK:MKGAF) to acquire U.S. biotech company SpringWorks Therapeutics (NASDAQ:SWTX) for an equity value of $3.9 billion to boost its cancer drug ...

Two months after saying it was in advanced talks to acquire SpringWorks Therapeutics, Merck KGaA, Darmstadt, Germany, has announced it agreed to purchase the developer of drugs for severe rare ...

Germany’s Merck KGaA agreed to acquire U.S. biopharmaceutical company SpringWorks Therapeutics for around $3.9 billion, in a bid to expand its oncology and rare disease business. The German life ...

Merck KGaA’s $3.9 billion deal to buy SpringWorks Therapeutics Inc. will expand the German conglomerate’s presence in the US at a time when many companies are seeking to increase investment in ...

You can reach Andrew on Signal at drewqjoseph.45. After months of discussion, Germany’s Merck KGaA said Monday it would buy SpringWorks Therapeutics for $47 a share in cash, a deal with an ...

Merck KGaA is edging closer to the SpringWorks deal, which was first rumoured in February, confirming late-stage negotiations at an estimated price of $47 per share – potentially valuing the ...

U.S. stock futures are little changed as investors ready for a busy earrings calendar, including upcoming reports from Apple, ...

April 24 (Reuters) - Germany's Merck KGaA (MRCG.DE), opens new tab said on Thursday it is in late-stage talks to acquire U.S.-based SpringWorks Therapeutics (SWTX.O), opens new tab for about $3.5 ...

Merck KGaA is nearing a deal to acquire SpringWorks Therapeutics Inc., people familiar with the matter said. An announcement may come as soon as Monday, the people said, asking not to be ...